NHIS Tops Korean Sustainability Index in Health and Welfare Sector

National Health Insurance Service (NHIS) has topped the Korean Sustainability Index (KSI) in the health and welfare sector at the 13th 2021 Korea Sustainability Rally at Lotte Hotel in downtown Seoul on Nov. 5. (Photos: NHIS)

National Health Insurance Service (NHIS) has ranked first in the Korean Sustainability Index (KSI) in the health and welfare sector at the 13th 2021 Korea Sustainability Rally at Lotte Hotel in downtown Seoul on Nov. 5.

KSI, based on the ISO 26000, the international standard for social responsibility, was evaluated on a survey of categories consisting of more than 25,000 participants, including community residents, cooperative companies and customers.

The latest KSI survey covered 48 industries and 202 companies and institutions. It was conducted to measure their social responsibility action levels and sustainability.

NHIS got the highest KSI score in the public sector, contributing to raising its status as a social responsibility leader.

NHIS was evaluated highly in recognition of coping with the COVID-19 pandemic, becoming the first public entity to have top integrity for the sixth consecutive year, and devoting itself to realizing social responsibility management by carrying out diverse social contribution activities.

Some of those activities include hiring the underprivileged, such as the seriously handicapped, creating jobs in the private sector, and promoting shared growth and invigoration of regional society.

NHIS President Kim Yong-ik said, “Our ranking 1st in the Korean Sustainability Index takes on significance since stakeholders participate to evaluate sustainability levels from their perspective.”

NHIS will make efforts to make people lead healthy life by putting into practice diverse social responsibility activities based on ESG management, he said.

(left) Minister Kim Kang-lip of the Ministry of Food and Drug Safety (MFDS), Vice Commissioner Kim Heon-joo of Korea Disease Control and Prevention Agency (KDCA) and President Kim Yong-ik of National Health Insurance Service (NHIS) attend a meeting designed to promote cooperation in securing the safety of medical productions and supporting the development of products based on real world evidence (RWE) at NHIS’s Yeouido Smart Work Center on Oct. 1.

MFDS, KDCA and NHIS Join Forces to Conduct Proactive Data Connectivity

The Ministry of Food and Drug Safety (MFDS), Korea Disease Control and Prevention Agency (KDCA) and National Health Insurance Service (NHIS) had a meeting to promote cooperation in securing the safety of medical products and supporting the development of products based on real world evidence (RWE) at NHIS’s Yeouido Smart Work Center on Oct. 1.

RWE in medicine means evidence obtained from real world data, which are observational data obtained outside the context of randomized controlled trials and generated during routine clinical practice.

During the meeting, each institution had vivid discussions how to verify the safety and effectiveness of new products or items now in use through organic connectivity and use of their own health and medical big data and secure scientific foundation for post-approval or follow-up safety management.

The three institutions agreed to cooperate in verifying of the safety and effectiveness of COVID-19 and other vaccines through their own data sharing and connectivity, working out ways of ensuring safety management of food and medical products through the building of their big data, and supporting analysis data to Korean vaccine developers.

They agreed to closely cooperate in proving the safety and effectiveness of vaccines based on RWE by sharing and connecting permission information of MFDS and information on abnormal reaction of vaccine inoculation of KDCA and information on requesting reimbursements of NHIS.

They plan to work out ways of ensuring safety management of foods and medical products based on actual data by building development, permission, production, distribution of medical products, reimbursements and information on abnormal reactions into big data of the whole cycle of medical products while supporting data analysis so that SK Bioscience and others can compare and consider clinical tests o homegrown vaccines and the safety of pregnant women and other targets.

The three also agreed to rationalize financial soundness of the health industry by comprehensively analyzing the quality, safety and effectiveness of drugs and evaluating prices of drugs.